Skip to main content
OpenTrials
Completed

NCT Number: NCT06703684

TCM Syndrome Differentiation of T2DM & MetS

This study aims to include type 2 diabetes (T2DM) patients comorbid with metabolic syndrome (MetS). The primary aim of the study is to investigate the TCM (Traditional Chinese Medicine) syndrome differentiation of T2DM comorbid with MetS.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Diabetes Mellitus, Type 2 Diabetes Mellitus Endocrine System Diseases Glucose Metabolism Disorders Hyperinsulinism Insulin Resistance Metabolic Diseases Metabolic Syndrome Nutritional and Metabolic Diseases

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Hong Kong Baptist University

Hong Kong

About this study

This study adopts a cross-sectional design, to include type 2 diabetes (T2DM) patients comorbid with metabolic syndrome (MetS). The primary aim of the study is to investigate the TCM (Traditional Chinese Medicine) syndrome differentiation of patients with T2DM and MetS. The demographic data, anthropometric data, fasting glucose and HbA1c, lipid panel, TCM syndrome differentiation information, dietary assessment, physical activity, sleep quality, and quality of life, will be assessed.

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • (1) Age between 18-75y.
  • (2) Diagnosed with Type 2 diabetes.
  • (3) Diagnosed with Metabolic Syndrome according to Guideline for the prevention and treatment of type 2 diabetes mellitus in China (2020 edition) from Chinese Diabetes Society. People who meet 3 of the following diagnostic criteria or more can be diagnosed as Metabolic Syndrome: (a) Abdominal obesity: waist circumference ≥ 90cm for male and ≥ 85cm for female; (b) Hyperglycemia: Fasting blood glucose ≥ 6.1mmol/L or 2-hour postprandial glucose ≥ 7.8mmol/L and/or those who have been diagnosed with hyperglycemia and in treatment; (c) Hypertension: blood pressure ≥ 130/85mmHg and/or those who have been diagnosed with hypertension and in treatment; (d) Fasting triglyceride ≥ 1.70mmol/L; (e) Fasting HDL-C < 1.04mmol/L.
  • (4) Clearly understand the content of the study and voluntarily sign the informed consent form.
  • (5) Provide complete data (basic information, TCM diagnosis data, and blood test results).

Exclusion criteria

  • (1) Diagnosed with type 1 diabetes, steroid-induced diabetes, gestational diabetes, or specific types of diabetes.
  • (2) Diabetes accompanied by severe complications such as diabetic nephropathy, diabetic ketoacidosis, etc.
  • (3) Secondary obesity (e.g., secondary to pituitary inflammation, tumor, etc.).
  • (4) Secondary hypertension (e.g., pheochromocytoma, renal hypertension, etc.).
  • (5) Secondary hyperlipidemia (e.g., hypothyroidism, nephrotic syndrome, etc.).
  • (6) With severe heart, liver, or kidney disease or bleeding disorders, or with other serious diseases (e.g. cancer, dementia, etc.).
  • (7) With severe mental disorders, speech or hearing impairments.
  • (8) Pregnancy or lactation female.
  • (9) Currently join other clinical trial.

Treatment and study plan

Cross-sectional observational study

Other

This is a cross-sectional observational study. No intervention will be given.

Primary outcomes

  1. TCM syndrome differentiation

    Time frame: Baseline

    A registered Chinese medicine practitioner (CMP) will conduct the TCM syndrome differentiation assessment using a standardized questionnaire, incorporating four TCM diagnostic methods.

Secondary outcomes

  1. Demographic data

    Time frame: Baseline

    Gender, date of birth, living status, marital status, education level, income status, occupation, work status, smoking history, alcohol consumption history, allergy history, medical history, etc.

  2. Anthropometric data

    Time frame: Baseline

    Anthropometric measurements such as skin fold thickness measurements.

  3. Fasting glucose

    Time frame: Baseline

    Fasting glucose level is measured.

  4. Lipid panel

    Time frame: Baseline

    Total cholesterol, triglycerides, high-density lipoprotein, low-density lipoprotein levels are measured.

  5. Hemoglobin A1c (HbA1c)

    Time frame: Baseline

    HbA1C level is measured.

  6. Framingham Stroke Risk Score (FSRS)

    Time frame: Baseline

    Framingham Stroke Risk Score (FSRS) is calculated based on variables such as age, cholesterol, blood pressure, diabetes, and smoking. Individuals with low risk have 10% or less risk at 10 years, with intermediate risk 10-20%, and with high risk 20% or more.

  7. International Physical Activity Questionnaire Short Form (IPAQ-SF)

    Time frame: Baseline

    International Physical Activity Questionnaire Short Form (IPAQ-SF) has been recommended as a cost-effective method to assess physical activity. The IPAQ-SF evaluates the number of days and time spent performing MVPA, walking, and sitting in bouts of at least 10 min over the previous 7 days. The summary score is expressed in PA metabolic equivalent of task (MET)-min per day or week.

  8. Audit of diabetes-dependent quality of Life (ADDQoL)

    Time frame: Baseline

    Audit of diabetes-dependent quality of Life (ADDQoL) consists of 2 overview items; one measures generic overall QoL and a further 19 items are concerned with the impact of diabetes on specific aspects of life. The scales range from -3 to +1 for 19 life domains (impact rating) and from 0 to +3 in attributed importance (importance rating). A weighted score for each domain is calculated as a multiplier of impact rating and importance rating (ranging from -9 to +3). Lower scores reflect poorer QOL.

  9. Pittsburgh sleep quality index (PSQI)

    Time frame: Baseline

    Pittsburgh sleep quality index (PSQI) was a 19-item questionnaire used to assess sleep dysfunction over a 1-month period. The total score for the PSQI varies from 0 to 21. A PSQI total score >5 is indicative of poor sleep.

  10. Dietary assessment

    Time frame: Baseline

    Dietary intake will be assessed via food frequency questionnaire (FFQ). The 60-item FFQ (<30 min for administration) with food items will be used.

Sponsors and collaborators

Lead sponsor

Hong Kong Baptist University

Other

Registry information

Official study title

TCM Syndrome Differentiation of Type 2 Diabetes Comorbid With Metabolic Syndrome

Important dates

Study start
2024
Primary completion
2025
Study completion
2025
First posted
Nov 25, 2024
Registry last updated
Mar 31, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.